CliffBio
small molecule

JOENJA

LENIOLISIB PHOSPHATE

Loss of exclusivityMarch 2030FDA regulatory exclusivity expiry
CompanyPHARMING TECHNOLOGIES BV

Drug detail

Brand nameJOENJA
Active ingredientLENIOLISIB PHOSPHATE
StrengthEQ 40MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2026
Marketing statusRX

Regulatory exclusivity

CodeExpires
ODE*March 2030
NSSeptember 2029
NCEMarch 2028

More from PHARMING TECHNOLOGIES BV

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.